Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication

Bor Shyang Sheu, Yu Ching Tsai, Chung Tai Wu, Wei Lun Chang, Hsiu Chi Cheng, Hsiao Bai Yang

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

Background and Aim: Intestinal metaplasia (IM) has overexpressions of COX-2. Short-term 8-week celecoxib, a selective COX-2 inhibitor, exerts a preliminary hint to improve regression in part for persistent IM after Helicobacter pylori eradication. This study further validated whether or not a prolonged duration of celecoxib of up to 1 year can be safe and effective. Methods: One hundred and forty patients, with persistent IM after H. pylori eradication for 1 year, were included with half of them receiving celecoxib 200 mg/day for 12 months and the other half serving as controls. Each patient received serial checkups of blood creatinine levels every 4 months. After the 1-year follow-up, panendoscopy was repeated to assess the IM regression. The serial gastric specimens, taken before and after celecoxib therapy, were immunochemically stained for COX-2. Results: The intention-to-treat (ITT) and per-protocol (PP) analyses to the rates of IM regression were higher in the celecoxib group than in the controls (ITT: 44.3% [31/70] vs 14.3% [10/70], p < .001; and PP: 51.7% [31/60] vs 16.1% [10/62], p < .001). All enrolled patients had no renal impairment during follow-up. Even in the patients without IM regression, the mean IM scores and COX-2 expressions were significantly more decreased in the celecoxib group than in the controls (p < .005). Conclusion: One year 200-mg celecoxib daily be safely administered to improve the regression or prevent the progression of persistent IM after H. pylori eradication.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalHelicobacter
Volume18
Issue number2
DOIs
Publication statusPublished - 2013 Apr

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication'. Together they form a unique fingerprint.

Cite this